Dogwood Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$28.0M | -$12.2M | -$5.4M | -$12.3M | -$15.6M |
| Operating expenses | $28.0M | $12.2M | $5.4M | $12.3M | $15.6M |
| Cash from operations | -$15.6M | -$8.8M | -$4.9M | -$11.5M | -$15.7M |
| Impairments | $0 | $0 | — | — | — |
| Total assets | $90.2M | $94.3M | $4.2M | $8.4M | $15.8M |
| Total liabilities | $15.3M | $30.0M | $358,548 | $1.0M | $1.3M |
Shares outstanding 33.6M · Free float 26.7%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.